New cancer drug AWT020 enters first human trial
NCT ID NCT06092580
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This early-phase trial is testing a new biologic drug called AWT020 in 60 adults with advanced solid tumors or lymphoma that have worsened after standard treatments. The main goals are to check the drug's safety at different doses and to see how the body processes it. Participants receive AWT020 by infusion every two weeks or longer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
AWT020 (a biologic drug given by infusion)
What this could lead to
If this trial shows AWT020 is safe and effective, it could point toward a new treatment option for people with advanced cancers that no longer respond to standard therapies.
What could go wrong
This is a very early (Phase 1/2) and small (60 people) trial, so it is not yet known if AWT020 works or is safe. Many experimental cancer drugs fail in early testing.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Alfred Health
RECRUITINGMelbourne, Victoria, Australia
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
ICON Cancer Center South Brisbane
RECRUITINGSouth Brisbane, Queensland, 4101, Australia
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Monash Medical Centre
RECRUITINGClayton, Victoria, 3168, Australia
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Southern Oncology Clinical Research Unit (SOCRU)
RECRUITINGBedford Park, South Australia, 5042, Australia
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••